Suppr超能文献

肾上腺皮质功能不全患者氢化可的松替代治疗中与体重相关的给药剂量、时间安排及监测

Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency.

作者信息

Mah Peak M, Jenkins Richard C, Rostami-Hodjegan Amin, Newell-Price John, Doane Anita, Ibbotson Victoria, Tucker Geoffrey T, Ross Richard J

机构信息

Division of Clinical Sciences (North), University of Sheffield, UK.

出版信息

Clin Endocrinol (Oxf). 2004 Sep;61(3):367-75. doi: 10.1111/j.1365-2265.2004.02106.x.

Abstract

OBJECTIVE

The objective of this study was to examine the variables determining hydrocortisone (HC) disposition in patients with adrenal insufficiency and to develop practical protocols for individualized prescribing and monitoring of HC treatment.

DESIGN AND PATIENTS

Serum cortisol profiles were measured in 20 cortisol-insufficient patients (09.00 h cortisol < 50 nmol/l) given oral HC as either a fixed or 'body surface area-adjusted' dose in the fasted or fed state. Endogenous cortisol levels were measured in healthy subjects. Pharmacokinetic analysis was performed using P-Pharm software, and computer simulations were used to assess the likely population distribution of the data.

RESULTS

Body weight was the most important predictor of HC clearance. A fixed 10-mg HC dose overexposed patients to cortisol by 6.3%, whereas weight-adjusted dosing decreased interpatient variability in maximum cortisol concentration from 31 to 7%, decreased area under the curve (AUC) from 50 to 22% (P < 0.05), and reduced overexposure to < 5%. Food taken before HC delayed its absorption. Serum cortisol measured 4 h after HC predicted cortisol AUC (r(2) = 0.78; P < 0.001).

CONCLUSIONS

We recommend weight-adjusted HC dosing, thrice daily before food, monitored with a single serum cortisol measurement using a nomogram. This regimen was prospectively examined in 40 cortisol-insufficient patients, 85% of whom opted to remain on the new thrice-daily treatment regimen.

摘要

目的

本研究旨在探讨决定肾上腺皮质功能不全患者氢化可的松(HC)处置的变量,并制定用于HC治疗个体化处方和监测的实用方案。

设计与患者

对20例皮质醇不足患者(上午9点皮质醇<50 nmol/L)进行血清皮质醇水平测定,这些患者在禁食或进食状态下接受固定剂量或“体表面积调整”剂量的口服HC。测定健康受试者的内源性皮质醇水平。使用P-Pharm软件进行药代动力学分析,并通过计算机模拟评估数据的可能总体分布。

结果

体重是HC清除率的最重要预测因素。固定10 mg HC剂量使患者皮质醇暴露过量6.3%,而根据体重调整剂量可使患者间最大皮质醇浓度的变异性从31%降至7%,曲线下面积(AUC)从50%降至22%(P<0.05),并使暴露过量减少至<5%。在服用HC之前进食会延迟其吸收。服用HC后4小时测得的血清皮质醇可预测皮质醇AUC(r² = 0.78;P<0.001)。

结论

我们建议根据体重调整HC剂量,每天三次在饭前服用,并使用列线图通过单次血清皮质醇测量进行监测。对40例皮质醇不足患者进行了前瞻性研究,其中85%的患者选择继续采用新的每日三次治疗方案。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验